Open AccessRational sequence of monoclonal antibodies in the treatment of non-resectable head and neck squamous cell carcinoma
Author(s) -
L. V. Bolotina,
Т. В. Устинова,
Т. И. Дешкина,
П. В. Голубев,
N. N. Lyubavina,
А. А. Феденко,
А. Д. Каприн
Publication year - 2022
Publication title -
opuholi golovy i šei
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.14
H-Index - 1
eISSN - 2411-4634
pISSN - 2222-1468
DOI - 10.17650/2222-1468-2022-12-1-35-52
Subject(s) - cetuximab , medicine , monoclonal antibody , concomitant , oncology , head and neck , chemotherapy , head and neck squamous cell carcinoma , regimen , clinical trial , head and neck cancer , basal cell , antibody , radiation therapy , surgery , immunology
This article discusses current approaches to first-line chemotherapy for non-resectable head and neck squamous cell carcinoma and describes factors affecting the choice of treatment regimen according to the results of randomized clinical trials. We provide a rationale for creating a long-term strategy of chemotherapy in different clinical situations. We also report two cases of concomitant administration of cetuximab and platinum-based therapy as an example of high efficacy of monoclonal antibodies.